AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01318824 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Nasal Intermittent Positive Pressure Ventilation (NIPPV)
Description: The Control group receiving Nasal Intermittent Positive Pressure Ventilation (NIPPV) treatment
Study NCT01318824 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bi-Level Positive Airway Pressure (BIPAP)
Description: BiPAP group receive Bi-Level Positive Airway Pressure (BIPAP) treatment
Study NCT02379689 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Injectable placental tissue extract called BioDGenesis (Active Product)
Study NCT02379689 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02410889 — intervention group
Intervention type: OTHER
Intervention: EEG-fMRI scanning
Description: Patients undergo EEG-fMRI scanning
Study NCT03449641 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Positive airway pressure (PAP)
Description: Positive airway pressure (PAP) is a mode of respiratory ventilation used in the treatment of sleep apnea.
Study NCT00228553 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Armodafinil 100 to 250 mg/day
Description: Armodafinil 100-250 mg: once daily in the morning for patients with obstructive sleep apnea/hypopnea syndrome (OSAHS) or narcolepsy, once daily only on nights worked for patients with shift worker sleep disorder (SWSD).
Study NCT03060070 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: control group
Description: 20ml of 0.25% bupivacaine will be injected in each side of the TAP block
Study NCT03246386 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Posaconazole Injection [Noxafil] 300mg
Description: Single dose by intravenous infusion 300mg
Study NCT03618511 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial Incentive
Description: Financial Incentive: Participants will receive monthly financial incentives each time they refill the ART medication on time for six months
Study NCT03618511 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reminders
Description: Reminders: Participants will receive monthly reminder phone calls before their ART medication refill is due for six months.
Study NCT03618511 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial Incentive and Reminders
Description: Interaction: Participants receive both the Financial Incentives and Reminder Calls.
Study NCT03618511 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Information
Description: Information: show the participants a video about HIV progression, mechanism of ART, the benefit of adhering to ART.
Study NCT03618511 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stigma-relieving
Description: Stigma-Reliving: Upon recruitment, inform the participants of the results of a recent population survey regarding people's attitudes towards HIV, if they overestimate the social stigma related to HIV. This intervention intends to reduce the stigma-concern faced by the patients.
Study NCT03618511 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Information and Stigma-relieving
Description: Information and Stigma-relieving: Upon recruitment, show the participants a video about HIV progression, mechanism of ART, the benefit of adhering to ART. In addition, inform the participants of the results of a recent population survey regarding people's attitudes towards HIV, if they overestimate the social stigma related to HIV. This intervention intends to reduce the stigma-concern faced by the patients.
Study NCT02300454 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non-slip element balloon (NSE)
Description: Lacrosse® NSE and SeQuent® Please drug coated balloon (DCB)
Study NCT02300454 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Balloon
Description: Non-compliant balloon and SeQuent® Please drug coated balloon (DCB)
Study NCT02318472 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VACOped orthosis
Description: Weight-bearing orthosis with adjustable range of motion of the ankle
Study NCT02318472 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Plaster cast
Description: Lower limb plaster cast
Study NCT01731678 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation
Description: The standardized treatment location will be the left DLPFC. Anatomical T1 images from the pre-intervention MRI will be loaded into our Transcranial Magnetic Stimulation (TMS) lab neuronavigation software (Brainsight2, Rogue Research, Montreal). Following 3D co-registration of the TMS coil with the patient's MRI images and head, the coil will be placed over the left DLPFC (tangential to scalp, angle of 45 degrees to midline). Interventional repetitive TMS (rTMS) (Magstim Rapid2, Wales, UK) will consist of 40 suprathreshold (120% RMT) pulses over 4 seconds (10 Hz) with an inter-train interval of 26 seconds. Treatment sessions will last 37.5 minutes (75 trains/3000 pulses). Treatments will occur on each weekday for three weeks (15 days total).
Study NCT00430170 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dipyridamole
Description: Dipyridamole 2x200mg 7day per os
Study NCT00430170 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dipyridamole
Description: Dipyridamole 2x200mg 7day per os
Study NCT00430170 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: caffeine
Description: caffeine 4mg/kg iv
Study NCT04206449 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic decision PSG
Description: Randomizing for therapeutic decision taken with Standard Polysomnography (PSG)
Study NCT04206449 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic decision Infrared thermgraphy system
Description: Also randomizing for Infrared thermography system
Study NCT03166332 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mediterranean diet
Description: Mediterranean diet supplemented with extra-virgin olive oil and nuts
Study NCT03166332 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness
Description: Mindfulness-Based Stress Reduction program (MBSR)
Study NCT00379795 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.5 mg
Description: Ranibizumab intravitreal injection 0.5 mg in a single-dose regimen given on an as needed basis no more frequently than every 30 days (no more than 12 injections per year)
Study NCT02956993 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vonapanitase
Study NCT02956993 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02507362 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: adjusted corneal collagen cross-linking
Description: UV-A irradiation for 7 minutes
Study NCT02507362 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: accelerated corneal collagen cross-linking
Description: UV-A irradiation for 10 minutes
Study NCT02507362 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: riboflavin 0.1% combined with dextran 20 %
Description: after mechanical epithelial removal riboflavin drop will be instilled every 5 minutes for 30 minutes and then instillation will be continued during irradiation
Study NCT02507362 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: riboflavin 0.1% combined with dextran 20 %
Description: after mechanical epithelial removal riboflavin drop will be instilled every 5 minutes for 30 minutes and then instillation will be continued during irradiation
Study NCT02507362 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: epithelial debridement
Description: corneal epithelium will be removed by a cottons swab
Study NCT02507362 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: epithelial debridement
Description: corneal epithelium will be removed by a cottons swab
Study NCT02387580 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OZ439 + TPGS
Study NCT02387580 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OZ439 Prototype 1
Study NCT02387580 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OZ439 Prototype 3
Study NCT02387580 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PQP
Study NCT02387580 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PQP
Study NCT00791271 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Starting dose of 10mg/m\^2 given daily via intravenous infusion on days 1-5 of 28 day cycle.
Study NCT00791271 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Interferon Alpha-2b
Description: Starting dose of 3 µg/kg injection under the skin once a week on days 1, 8, 15, and 21 of 28 day cycle.
Study NCT01352806 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: identification of the lumbar interspinous space using fluoroscopy versus ultrasound versuspalpation
Description: Copmarison of multiple technique for identification of the lumbar interspinous space,which is fluoroscopy,ultrasound and palpation
Study NCT01373983 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ziconotide
Description: 1.25 or 2.5 mcg or 3.75 mcg i.t. according to an algorithm
Study NCT01613755 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin, dipyridamole
Description: Metformin 500 mg twice daily for four days Dipyridamole 200 mg twice daily for four days
Study NCT01613755 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin 500 mg twice daily for four days
Study NCT03965559 — intervention group
Intervention type: PROCEDURE
Intervention: plasmapheresis
Description: Plasmapheresis is the removal, treatment, and return or exchange of blood plasma or components thereof from and to the blood circulation. It is thus an extracorporeal therapy (a medical procedure performed outside the body).\[Wikipedia\]~DFPP is a selectively removal of the immunoglobulin fraction from the serum and, as a result, to minimize the volume of substitution fluid required. \[Tanabe K. Double-filtration plasmapheresis. Transplantation. 2007 Dec 27;84(12 Suppl):S30-2.\]
Study NCT01175291 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MK-0646
Description: ARM A will receive FOLFOX 7 (Oxaliplatin with leucovorin + 5-Fluorouracil \[5-FU\] + Bevacizumab) + MK-0646 (Investigational).
Study NCT01175291 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: ARM B will receive FOLFOX 7 (Oxaliplatin with leucovorin + 5-Fluorouracil \[5-FU\] + Bevacizumab) + placebo: standard of care chemotherapy plus placebo.
Study NCT01219231 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: 6 months of aerobic exercise
Study NCT01219231 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Exercise
Description: 6 months of aerobic exercise
Study NCT03170674 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FT21039
Description: an electronic cigarette product
Study NCT03170674 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FT21092
Description: an electronic cigarette product
Study NCT03170674 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FT21018
Description: an electronic cigarette product
Study NCT02372487 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sildenafil citrate
Description: sildenafil citrate 25 mg every 8 hours
Study NCT02372487 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: fluid therapy
Description: 2 liters of fluid per day
Study NCT02686086 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: vibrating mesh nebuliser
Description: The Aerogen Solo vibrating mesh nebuliser is an approved 13 485 class II medical device (CE marked) nebuliser licenced for the delivery of physician-prescribed medications for inhalation which are approved for use with a general purpose nebuliser. It has been shown in previous laboratory and clinical studies to have superior drug delivery to standard jet nebulisers.
Study NCT02686086 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Standard hospital jet nebuliser
Description: The standard hospital jet nebuliser refers to the nebuliser in clinical use currently throughout Beaumont Hospital and used for the administration of nebulised medications
Study NCT02686086 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Combined salbutamol 2.5 mg and ipratropium 0.5mg nebule
Description: All patients admitted to hospital with an exacerbation of COPD are administered nebulised bronchodilators (salbutamol 2.5mg/ipratropium 0.5mg combination) as standard of care
Study NCT02686086 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Combined salbutamol 2.5 mg and ipratropium 0.5mg nebule
Description: All patients admitted to hospital with an exacerbation of COPD are administered nebulised bronchodilators (salbutamol 2.5mg/ipratropium 0.5mg combination) as standard of care
Study NCT01309035 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total Knee Arthroplasty
Description: Surgery for OA knee pains
Study NCT01309035 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total Knee Arthroplasty
Description: Surgery for OA knee pains
Study NCT03768947 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heat therapy via hot water immersion
Description: Participants will be asked to participate in a 4-week heat therapy intervention, which consists of \~12-15 visits (45 min each) of immersion in to a hot tub.
Study NCT04576598 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-management program to increase physical activity levels
Description: Information and Communication Technologies will be used to carry out various remote sessions. The sessions will address important issues to promote self-management of sedentary lifestyle by stroke survivors. Additionally, a peer support group will be created in order to improve adherence to the program.
Study NCT04576598 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Education information
Description: Education on the importance of active lifestyle habits post-stroke.
Study NCT02447315 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pilocarpine
Description: oral
Study NCT03246386 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Posaconazole Injection [Noxafil] 300mg
Description: Single dose by intravenous infusion 300mg
Study NCT03246386 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Posaconazole Injection [Noxafil] 400mg
Description: Single dose by intravenous infusion 400mg
Study NCT04167878 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3D printed biodegradable cervical fusion cage
Description: ACDF with 3D printed biodegradable cervical interbody fusion cage for spinal fusion procedure at one level (C2 to T1) of the cervical spine.
Study NCT04167878 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PEEK cage
Description: ACDF with PEEK cage for spinal fusion procedure at one level (C2 to T1) of the cervical spine.
Study NCT03381976 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intervention 2X/week (G2X)
Description: Participants performed resistance training (RT) composed of eight exercises performed for one set of 10-15 repetition maximum (RM). The rest interval between exercises was 2-3 min. Participants were instructed to control the speed of movement in the ratio of 1:2 for concentric and eccentric muscle actions, respectively. The progression of training loads in each exercise occurred, when a participant completed 15 repetitions in two consecutive sessions, with increases of 2-5% in exercises for the upper limbs, and 5-10% in exercises for the lower limbs. At the end of each session, one static stretching exercise at the point of discomfort for 15 seconds was performed for all major muscle groups for a total of exercises. Participants were asked not to perform any other type of organized physical exercise during the entire study period.
Study NCT03381976 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intervention 3X/week (G3X)
Description: Participants performed resistance training (RT) composed of eight exercises performed for one set of 10-15 repetition maximum (RM). The rest interval between exercises was 2-3 min. Participants were instructed to control the speed of movement in the ratio of 1:2 for concentric and eccentric muscle actions, respectively. The progression of training loads in each exercise occurred, when a participant completed 15 repetitions in two consecutive sessions, with increases of 2-5% in exercises for the upper limbs, and 5-10% in exercises for the lower limbs. At the end of each session, one static stretching exercise at the point of discomfort for 15 seconds was performed for all major muscle groups for a total of exercises. Participants were asked not to perform any other type of organized physical exercise during the entire study period.
Study NCT02989454 — intervention group
Intervention type: OTHER
Intervention: Assessment of exercise capacity and cardiac energetics
Description: Cardiopulmonary exercise testing and Magnetic Resonance Spectroscopy
Study NCT02356900 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hyperoxic hyperbaric interval exercise training
Description: Six 30-min high-intensity interval training sessions completed 3-times a week while at 1.4 ATA of oxygen in a hyperbaric chamber.
Study NCT02356900 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Normoxic, normobaric, interval exercise training
Description: Six 30-min high-intensity interval training sessions completed 3-times a week.
Study NCT02356900 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxygen
Description: Used in Hyperoxic hyperbaric interval exercise training intervention
Study NCT03567343 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Proprietary Spearmint Extract Blend
Description: Water extracted spearmint extract and green tea blend
Study NCT03567343 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Placebo
Study NCT04517890 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lidocaine patch
Description: 5% lidocaine patch applied at 3 hours before the procedure
Study NCT04517890 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sham patch
Description: Sham patch containing no study medication applied 3 hours before the procedure
Study NCT01074385 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Dignity Therapy
Description: Dignity therapy is a psychotherapeutic intervention developed to address psychosocial and existential distress among terminally ill patients. Basically, it invites patients to discuss topics that matter most or how they want to be remembered. This interview is recorded and then edited and returned to the patient to be used for further reflection or for sharing with loved ones.
Study NCT02753439 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Geistlich Bio Oss
Description: Extraction of Impacted 3rd Molars,
Study NCT05786742 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: grade and compare reported side effects between groups
Description: Compare experimental ultra hypo fractionation (25 Gy in 5 daily fractions administered starting mid week and ending mid following week) to our standard fractionation (either 37,5 Gy given in 15 daily fractions, or 36 Gy in 12 daily fractions).~* Toxicity analysis will be quantitatively evaluated using CTCAE (v5) at 1, 2 and 5 years post-therapy, and has needed at FU visits. Kaplan-Meier statistical analysis will be used to report toxicity evolution through time.~* median IPSS scores will be reported at 3, 6, 12 months and yearly (1, 2, 3, 4 et 5) post-therapy. IPSS median time to baseline return will be calculated.~* IPSS urinary scores, sexual function (SHIM) and GI toxicity (CTCAE-v5) and quality of life questionnaires ( EPIC-26) will be given at 3, 6 months and yearly thereafter (1, 2, 3, 4 et 5) post-treatment.
Study NCT05786742 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: grade and compare reported side effects between groups
Description: Compare experimental ultra hypo fractionation (25 Gy in 5 daily fractions administered starting mid week and ending mid following week) to our standard fractionation (either 37,5 Gy given in 15 daily fractions, or 36 Gy in 12 daily fractions).~* Toxicity analysis will be quantitatively evaluated using CTCAE (v5) at 1, 2 and 5 years post-therapy, and has needed at FU visits. Kaplan-Meier statistical analysis will be used to report toxicity evolution through time.~* median IPSS scores will be reported at 3, 6, 12 months and yearly (1, 2, 3, 4 et 5) post-therapy. IPSS median time to baseline return will be calculated.~* IPSS urinary scores, sexual function (SHIM) and GI toxicity (CTCAE-v5) and quality of life questionnaires ( EPIC-26) will be given at 3, 6 months and yearly thereafter (1, 2, 3, 4 et 5) post-treatment.
Study NCT02600780 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Febuxostat
Description: Comparison of two anti-hyperuricemic molecules
Study NCT02600780 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Allopurinol
Description: Comparison of two anti-hyperuricemic molecules
Study NCT04491071 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Generalized Anxiety Disorder-7 (GAD 7)
Description: test that will evaluate persistent and excessive worry about a number of different things. People with Generalized Anxiety Disorder may anticipate disaster and may be overly concerned about money, health, family, work, or other issues. Individuals with Generalized Anxiety Disorder find it difficult to control their worry.